Phase II interventional study (N0337) of capecitabine in combination with vinorelbine and trastuzumab for first- or second-line treatment of HER2-positive metastatic breast cancer: a north central cancer treatment group trial (Q42633443)

From Wikidata
Jump to navigation Jump to search
scientific article published on April 2012
edit
Language Label Description Also known as
English
Phase II interventional study (N0337) of capecitabine in combination with vinorelbine and trastuzumab for first- or second-line treatment of HER2-positive metastatic breast cancer: a north central cancer treatment group trial
scientific article published on April 2012

    Statements

    Phase II interventional study (N0337) of capecitabine in combination with vinorelbine and trastuzumab for first- or second-line treatment of HER2-positive metastatic breast cancer: a north central cancer treatment group trial (English)
    1 reference
    Winston W Tan
    1 reference
    Jacob B Allred
    1 reference
    Muhammad Salim
    1 reference
    Patrick Flynn
    1 reference
    Paul A S Fishkin
    1 reference
    Philip J Stella
    1 reference
    Martin Wiesenfeld
    1 reference
    Albert M Bernath
    1 reference
    Tom R Fitch
    1 reference
    1 April 2012
    1 reference
    12
    1 reference
    81-86
    1 reference

    Identifiers

     
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    edit